SākumlapaMEHCQ • OTCMKTS
add
23andMe Holding Co.
Slēgšanas kurss
1,17 $
Dienas diapazons
1,07 $ - 1,18 $
Gada diapazons
0,48 $ - 12,76 $
Tirgus kapitalizāc.
30,85 milj. USD
Vid. apjoms
8,09 milj.
P/E koeficients
-
Ienākumi no dividendēm
-
Galvenā birža
OTCMKTS
Ziņās
Par
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Dibināšanas datums
apr. 2006
Galvenais birojs
Tīmekļa vietne
Darbinieki
571